Clarivate Plc Stock Price, News & Analysis

Clarivate (NYSE:CLVT) reported Q2 2025 results with total revenues of $621.4 million, down from $650.3 million in Q2 2024 due to divestitures. The company showed positive trends with organic revenue growth of 0.5% and organic ACV growth of 1.3%. Notably, organic recurring revenue mix improved to 88%, up 800 basis points from year-end 2024.

Q2 2025 net loss was $72.0 million ($0.11 per share), improving from a $304.3 million loss in Q2 2024. Adjusted EBITDA reached $261.6 million. The company generated $287.5 million in operating cash flow and repurchased 11.5 million shares in Q2. Management reaffirmed its 2025 outlook, projecting revenues of $2.28B-$2.40B and adjusted EBITDA of $940M-$1.00B.

[ "Organic revenue growth of 0.5% and organic ACV growth of 1.3%", "Improved recurring revenue mix to 88%, up 800 basis points from 2024", "Net loss improved significantly to $72.0M from $304.3M in Q2 2024", "Generated strong operating cash flow of $287.5M in H1 2025", "Executed share repurchase of 23.2M shares at average price of $4.29" ]

Clarivate (NYSE:CLVT) has released its 2025 G20 research and innovation scorecard, offering comprehensive insights into global research collaboration and impact. The enhanced scorecard now includes data from the Emerging Sources Citation Index (ESCI) and features new metrics focusing on open access and SDG-aligned research.

Key findings reveal that Mainland China leads G20 research output with 900,000 papers in 2024, triple its 2015 volume. The European Union has doubled its collaboration with China to 6.6%, while the UK has increased international collaboration from 55% to 70% over the past decade. The United States maintains 43% international collaboration, with China being its largest international partner.

The interactive scorecard, available on Clarivate.com, launches ahead of the G20 Summit in Johannesburg, incorporating OECD field-level breakdowns and enhanced visualization tools.

Clarivate (NYSE:CLVT), a global provider of transformative intelligence, has scheduled its second quarter 2025 financial results announcement for July 30, 2025, before market opening.

The company will host a conference call and webcast at 9:00 AM Eastern Time on the same day. The earnings release and supplementary materials will be available on Clarivate's investor relations website. U.S. participants can join via 800-715-9871, while international participants can dial +1 646-307-1963 using conference ID 7007526.

Clarivate (NYSE:CLVT) has released its 2025 Journal Citation Reports (JCR), marking the 50th anniversary of these influential publications. The reports cover 22,249 journals across 254 categories, with 6,200 published via gold open access. The JCR includes journals from 111 countries, comprising 14,591 in sciences, 7,559 in social sciences, and 3,368 in arts and humanities. A significant update in 2025 excludes citations from retracted content in Journal Impact Factor (JIF) calculations while maintaining transparency by including retracted articles in the denominator, affecting 1% of journals. The reports continue to provide publisher-neutral data and metrics, including the widely-used JIF and Journal Citation Indicator, helping academic institutions, researchers, and publishers evaluate journal trustworthiness and impact.

Clarivate (NYSE:CLVT) has released a new Companies to Watch report focused on radioligand therapy (RLT) innovators in precision oncology. The report highlights six emerging companies: Affibody, Alpha-9 Oncology, Ariceum Therapeutics, Convergent Therapeutics, Perspective Therapeutics, and PRECIRIX, who are advancing next-generation radiopharmaceuticals. RLTs combine nuclear medicine with targeted biotechnology to deliver radioactive isotopes directly to tumor cells while minimizing damage to healthy tissue. The report examines scientific breakthroughs, strategic investments, M&A activity, and market trends, noting significant acquisitions like Bristol Myers Squibb's $4.1B purchase of RayzeBio and AstraZeneca's $2.4B acquisition of Fusion Pharmaceuticals. The global radiopharmaceutical market is projected to exceed $13B in the next decade, with successful therapies like Novartis' PLUVICTO and LUTATHERA leading adoption.

Clarivate (NYSE:CLVT) has become the first sponsor of the American Library Association's (ALA) Public Supporter Program, marking a significant expansion of their long-standing partnership. The program, launched in February 2025, aims to engage the public in supporting libraries and library professionals through advocacy, news sharing, and community involvement. The two-year sponsorship running until 2027 will support key ALA initiatives including library funding advocacy, grant opportunities for small and rural libraries, protection of reading rights, and broadband funding. Bar Veinstein, President Academia & Government at Clarivate, emphasized the company's commitment to supporting libraries as essential educational institutions. ALA President Cindy Hohl acknowledged Clarivate's deepening commitment to strengthening library services across the United States.

Clarivate (NYSE:CLVT) has established a multi-year partnership with the Canadian Research Knowledge Network (CRKN), extending through 2029. The collaboration provides 55 Canadian universities expanded access to the Web of Science platform, including its Core Collection, API, Derwent Innovations Index, and Policy Citation Index. This partnership aims to enhance research collaborations and improve access to comprehensive research tools across Canadian institutions. The Web of Science platform offers access to various research materials, including journal content, conference papers, books, dissertations, datasets, patents, and policy documents. The agreement particularly emphasizes supporting Canadian research initiatives, which have been noted to exceed international averages in innovation and patents.

Clarivate (NYSE: CLVT) has successfully completed a refinancing of its debt structure by securing a new $500 million term loan B facility maturing in 2031. The new loan carries an interest rate margin of 325 basis points per annum referenced to term SOFR and will not require amortization. The proceeds were used to redeem $500 million of the company's 4.50% senior secured notes due 2026, leaving $200 million of these notes still outstanding. The refinancing effectively extends the maturity of the majority of Clarivate's 2026 debt obligations. CFO Jonathan Collins highlighted that improved credit market conditions enabled this transaction, emphasizing the company's strong cash flow position and continued flexibility in capital allocation.

Clarivate (NYSE:CLVT) has renewed and expanded its partnership with CAPES, Brazil's key education agency, in a landmark five-year agreement. The collaboration extends access to critical research tools and data across over 400 Brazilian institutions, marking a 57% increase in institutional coverage. The partnership provides access to essential platforms including Web of Science, Journal Citation Reports, Cortellis Drug Discovery Intelligence, and Derwent Innovation Index. This expansion particularly benefits institutions in remote regions, supporting CAPES' mission to reduce regional disparities in academic research. The agreement builds on a relationship that began in 2001, empowering researchers, scholars, and healthcare professionals with comprehensive data access. Brazil's research output shows strong international collaboration, with 40% of output being internationally collaborative and demonstrating above-average impact in medicine and significant focus on Life Sciences and Sustainable Development Goals.